21SEP

Alchemab wins Bank's record £25m cheque

2 min read

16:52UTC

Alchemab Therapeutics raised a £25m Series A extension on 9 July, the British Business Bank's largest-ever direct life-sciences cheque, for AI-enabled antibody discovery.

← Back to Nscale takes $103.4bn of contracts to NYSE Jump to analysis ↓

TechnologyAssessed

Key takeaway

Alchemab's £25m is the Bank's biggest life-sciences bet, staking public money on AI antibody discovery.

Alchemab Therapeutics, a British antibody-discovery biotech, raised a £25m Series A extension on 9 July, the largest direct life-sciences investment the British Business Bank has ever made, to push an AI-enabled antibody-discovery pipeline toward the clinic ¹.

Alchemab hunts for protective antibodies in people who resist diseases they should have caught, then turns those molecules into drug candidates. The method leans on machine learning to sift immune repertoires at a scale no bench scientist could match, placing it in the same AI-meets-biology tier as IMU Biosciences, which raised £40m in June .

The cheque puts the state directly on a life-sciences cap table rather than behind a fund manager. For a Bank criticised for leading none of the year's marquee AI rounds, backing Alchemab plants a flag in a field where British Science still leads. Someone still has to run those assays, and the government published a plan to build that workforce the same afternoon.

Deep Analysis

In plain English

Alchemab Therapeutics is a Cambridge biotech using artificial intelligence to find antibodies, proteins the immune system makes to fight disease, that could become new drugs. On 9 July it raised £25m as an extension to an earlier funding round, and all of it came from the British Business Bank, a state-owned bank that invests in growing UK companies. It is the largest single life-sciences investment the Bank has ever made directly. The money should let Alchemab keep developing its antibody candidates towards human clinical trials without needing to raise again from private investors in the near term.

Deep Analysis

Root Causes

Alchemab's cheque exists because the Bank's mandate changed in April: for the first time it can lead venture rounds and invest directly up to £60m per company, rather than only co-investing alongside private leads as it did in IMU Biosciences' £40m round.

Pre-clinical antibody discovery is capital-intensive with a long return horizon, a profile private venture funds have grown warier of funding alone since 2023; the Bank's expanded mandate exists specifically to backstop that gap in patient capital.

What could happen next?

Meaning
The Bank's willingness to write £25m directly into a pre-clinical biotech signals it now treats life-sciences extension rounds as within its risk appetite, not just seed-stage deeptech.

Source Landscape

This story draws on neutral-leaning sources

Primary parallel: The Bank contributed £12m to Cytospire Therapeutics' £61m Series A in May, one investor among a syndicate led by 4BIO Capital; Alchemab's £25m two months later, with the Bank as sole backer, shows the size of a single Bank life-sciences cheque roughly doubling in the space of two months.

Counter-parallel: In Oxford Quantum Circuits' £260m Series C, the Bank was one of nine co-investors in a syndicate led by Bullhound Capital; Alchemab is the opposite structure, a single-investor cheque with no syndicate at all, a role the Bank has not previously taken at this size in life sciences.

Immediate effect: £25m extends Alchemab's runway toward clinical-stage antibody candidates without the down round or bridge financing pre-clinical biotechs often need when a Series A closes before trial data reads out.

Structurally, this is the Bank's largest direct life-sciences cheque under the £6.6bn mandate it has held since April, a scale test of whether a state investor can underwrite biotech risk at a size previously reserved for specialist life-sciences funds.

Consensus view: The BioIndustry Association's general position is that the UK's life-sciences financing gap sits at Series A extension and Series B, not seed, where US and European AI-biotech comparators typically outspend British rounds by two to three times; the Bank's £25m cheque targets exactly that stage.

Counter-view: Some UK venture investors argue a government-backed direct-equity cheque can crowd out the private syndicates that would otherwise lead extension rounds, since Bank capital can anchor a round on terms private investors did not set, echoing the dynamic already visible in IMU Biosciences' £40m raise , where the Bank co-invested rather than led.

Key tension: Whether the Bank's willingness to write the largest cheque should be read as filling a genuine market gap or as substituting for private capital that has grown more risk-averse toward pre-clinical antibody discovery.

Sources:British Business Bank

Mentions:Bullhound Capital →Oxford Quantum Circuits →Trimtech Therapeutics →British Business Bank →IMU Biosciences →Cytospire Therapeutics →Cambridge →Alchemab Therapeutics →

First Reported In

Update #11 · Britain funds and defunds its own science

British Business Bank· 14 Jul 2026

Read original →

Causes and effects

Caused by

IMU raises £40m to read blood

IMU Biosciences' £40m June round set the AI-biotech benchmark that Alchemab's £25m cheque extends.

Occurred 2 Jun 2026

Read story →

Jobs plan targets the lab-skills gap

The Jobs Plan answers the staffing gap that Alchemab's £25m cheque assumes is already solved.

Occurred 9 Jul 2026

Read story →

This Event

Alchemab wins Bank's record £25m cheque

The investment puts UK public money directly on a biotech cap table, not behind a fund manager, in a sector British science still leads.

Different Perspectives

Nscale and Open Cosmos

Nscale chose the New York Stock Exchange for its listing on 18 September, putting Britain's largest AI infrastructure bet to American public investors rather than British ones. Open Cosmos took the opposite route four days earlier, raising nine figures from an all-domestic syndicate on five years of profit, evidence that staying is possible when the balance sheet allows it.

Dame Chi Onwurah and the Science, Innovation and Technology Committee

Committee chair Dame Chi Onwurah wrote to government on 7 September asking how Matt Clifford's conflict at ARIA arose and what safeguards protect its governance, and expects a detailed response. Her question has not yet been put to the Sovereign AI Unit, whose own chair sits at a venture capital firm while overseeing state AI equity.

The Entrepreneurs Network

The Entrepreneurs Network's founder survey found 65% say Britain is easy to start a business in but only 14% say it is easy to scale one, with 82% negative on tax and 74% finding investment hard to access. On this reading the constraint is regulation and tax, not the capital-vehicle design the state keeps adjusting.

New Economics Foundation

The New Economics Foundation argues fiscal accounting rules, not political will, cap what Britain's state capital vehicles can do. Matching the KfW and Bpifrance benchmark of 1% of GDP would need the National Wealth Fund to deploy roughly GBP21bn a year by 2028-29, about four times its current capacity.

Competition and Markets Authority

The CMA's 8 September report on public procurement asked whether Britain's roughly GBP400bn state-spending system is built to grow high-potential firms rather than simply widen SME participation. Its Recommendation 5 calls for a dedicated frontier-technology procurement framework, an official acknowledgement that today's design may serve the wrong target.

Highland Europe

Highland Europe, the growth-equity firm behind a €1bn-plus fund, took €65m from the British Business Bank into its Technology Growth Fund VI on 30 July via British Patient Capital. For a Geneva-based growth investor, the Bank's cheque is routine cornerstone capital, unrelated to which Whitehall department currently claims to sponsor UKRI.